For its second fiscal quarter (ending June 30), United Therapeutics Corp (NASDAQ: UTHR) has reported E.P.S. of $6.26 compared to $5.53 a year ago. E.P.S. were $23.12 for the latest four quarters through June 30 […]
QUALCOMM Inc. (NASDAQ: QCOM) has reported E.P.S. of $1.89 for its third fiscal quarter (ending June 30) versus $1.56 for the same period a year ago. For the latest four quarters through June 30, E.P.S. […]
Lantheus Holdings Inc (NASDAQ: LNTH) has reported E.P.S. of $0.89 for its second fiscal quarter (ending June 30) versus $1.38 for the same period a year ago. E.P.S. were $6.24 for the latest four quarters […]
Gold Fields Ltd (NYSE: GFI). Meaningful positive changes in fundamentals have recently occurred: the consensus estimate for December, 2025 increased significantly, the consensus estimate for December, 2024 increased significantly, and significant quarterly earnings acceleration occurred. […]
Important positive changes in Sarepta Therapeutics Inc (NASDAQ: SRPT) fundamentals have recently occurred: the consensus estimate for December, 2024 increased significantly, significant quarterly sales acceleration occurred, and the consensus estimate for December, 2025 increased significantly. […]
Norwegian Cruise Line Holdings L (NYSE: NCLH) has reported earnings for its second fiscal quarter (ending June 30) of $0.38 versus $0.20 for the same period a year ago. For the latest four quarters through […]
Everest Re Group Ltd (NYSE: RE) has reported E.P.S. of $16.70 for its second fiscal quarter (ending June 30) versus $16.26 for the same period a year ago. For the latest four quarters through June […]
Costamare Inc (NYSE: CMRE) has reported earnings for its second fiscal quarter (ending June 30) of $0.77 versus $0.52 for the same period a year ago. E.P.S. were $2.83 for the latest four quarters through […]
Artio Global Investors Inc (NASDAQ: AVGO) stock closed at $160.68 on 7/31/24 after a major increase of 12.0%. This advance was accompanied by normal trading volume. The stock has declined -1.9% during the last week […]
For its second fiscal quarter (ending June 30), Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has reported E.P.S. of $-0.08 compared to $0.03 a year ago. E.P.S. were $-0.19 for the latest four quarters through June 30 […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research